Recommendation on the nomenclature for oral anticoagulants: Communication from the SSC of the ISTH: Comment

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 11, 2015, Pages 2130-2132

  Husted, S ^a   Lip, G Y H ^b   De Caterina, R ^c  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 9; DABIGATRAN ETEXILATE; EDOXABAN; NON VITAMIN K ANTAGONIST ORAL ANTICOAGULANT; RIVAROXABAN; TARGET SPECIFIC ORAL ANTICOAGULANT; UNCLASSIFIED DRUG;

BLOOD CLOTTING; DRUG CLASSIFICATION; DRUG EFFECT; DRUG NOMENCLATURE; DRUG RESEARCH; ENZYME ACTIVITY; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; CLASSIFICATION; DRUG EFFECTS; HUMAN; NOMENCLATURE;

ANTICOAGULANTS; BLOOD COAGULATION; HUMANS; TERMINOLOGY AS TOPIC;

EID: 84948686593     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13124     Document Type: Letter

References (10)

1. Barnes GD, Ageno W, Ansell J, Kaatz S, for the Subcommittee on the Control of Anticoagulation. Recommendation on the nomenclature for oral anticoagulants: communication from SSC of the ISTH. J Thromb Haemost 2015; 13: 1-3.
2. Husted S, de Caterina R, Andreotti F, Arnesen H, Bachmann F, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Storey RF, Weitz JI, ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. Thromb Haemost 2014;111:781-2.
3. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen S, Lip G, Morais J, Rasmussen L, Siegbahn A, Verheugt F, Weitz J. General mechanisms of coagulation and targets of anticoagulants (Section I) - position paper of the ESC Working Group on Thrombosis - task force on anticoagulants in heart disease. Thromb Haemost 2013; 109: 569-79.
4. Ansell J, Crowther M, Burnett A, Garcia D, Kaatz S, Lopes RD, Nutescu E, Oertel L, Schnurr T, Streiff M, Wirth D, Witt D, Wittkowsky A, Anticoagulation Forum. Comment on: editorial by Husted et al. 'Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel'. (Thromb Haemost 2014;111:781-2). Thromb Haemost 2014;112:841.
5. Husted S, Lip GY, ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Response to Ansell et al. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. (Thromb Haemost 2014;112:841). Thromb Haemost 2014;112:842.
6. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa UM, Taggart DP, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-619.
7. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Hausler KG, Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consessus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asian-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35: 3155-79.
8. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013; 34: 2094-106.
9. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurica Galié N, Gibbs JS, Huisman MV, Humbert M, Hucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, et al.; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014;35:3033-69.
10. Camm JA, Pinto FJ, Hankey GJ, Andreotti F, Hobbs FDR on behalf of the Writing Committee of the Action for Stroke Prevention alliance. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace 2015;17:1007-17.